No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVO240719P150000
- 20.80
- +5.85+39.13%
15min DelayClose Jul 18 16:00 ET
20.80High16.95Low
16.95Open14.95Pre Close781 Volume240 Open Interest150.00Strike Price1.61MTurnover0.00%IV0.61%PremiumJul 19, 2024Expiry Date20.01Intrinsic Value100Multiplier1DDays to Expiry0.79Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.54Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Novo Nordisk on Pace for Largest Percent Decrease Since February 2023 -- Data Talk
Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $129.23, down $6.19 or 4.57% --Would be lowest close since May 10, 2024, when it closed at $128.42 --On pace for largest percent decrease
Eli Lilly's Stock Plunges as Investors Eye Obesity-drug Competition
By Eleanor Laise 'Vast' weight-loss drug pipeline keeps Lilly in a strong position as field gets crowded, analysts say Eli Lilly & Co.'s stock was on pace for its worst day in about three years
Eli Lilly, Novo Extend Muti-day Decline in Rare Selloff
Express News | Shares of Weight Loss Stocks Are Trading Lower, Possibly on Continued Weakness Following Recent Weight Loss Data From Roche, Which Could Cause Competition Concerns for Companies in the Space
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
European equities traded in the US as American depositary receipts were moving moderately lower late Thursday morning, declining 0.72% to 1,423.26 on the S&P Europe Select ADR Index.From continental
Top Gap Ups and Downs on Wednesday: TSM, NVO, ASML and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Comments
$ROCHE HOLDING AG(RHHBY.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
5
Chip tensions
Global chip stocks tumbled amid potentially tighter restrictions on U.S. exports to China and escalating geopolitical tensions. U.S.-listed shares of ASML and Taiwan Semiconductor Manufacturing Co plunged 12% and 8%, respectively. The declines followed a Bloomberg report that the Biden administration is weighing tougher restrictions on companies exporting technology to China.
Nvidia shares slumped more than 6%, while Arm Holdings, Lam Research, Applied M...
Global chip stocks tumbled amid potentially tighter restrictions on U.S. exports to China and escalating geopolitical tensions. U.S.-listed shares of ASML and Taiwan Semiconductor Manufacturing Co plunged 12% and 8%, respectively. The declines followed a Bloomberg report that the Biden administration is weighing tougher restrictions on companies exporting technology to China.
Nvidia shares slumped more than 6%, while Arm Holdings, Lam Research, Applied M...
2
1
$Novo-Nordisk A/S(NVO.US$ Novo Nordisk receives Complete Response Letter in the US for Thomson Reuters (11/07/2024) Bagsværd, Denmark, 10 July 2024 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete
Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufac...
Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufac...
2
Read more